|
| Wednesday, 1 June 2016, 14:19 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
TOKYO, June 1, 2016 - (JCN Newswire) - AbbVie GK (Headquarters: Tokyo, President: James C. Feliciano, "AbbVie"), Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and its subsidiary EA Pharma Co., Ltd. (Headquarters: Tokyo, CEO: Hajime Shimizu, "EA Pharma"), announced that EA Pharma and AbbVie will commence the co-promotion of fully human anti-TNF-alpha monoclonal antibody HUMIRA for indications in the field of gastrointestinal disease (ulcerative colitis, Crohn's disease, intestinal Behcet's disease) as of today.
Established in April 2016 through the integration of Eisai's gastrointestinal disease business and AJINOMOTO PHARMACEUTICALS Co., Ltd., EA Pharma is a gastrointestinal specialty pharma with a full value chain including research and development, production and logistics, sales and marketing. EA Pharma has been delegated by Eisai to undertake co-promotion on gastrointestinal disease indications for HUMIRA with Abbvie.
Furthermore, there will be no change to the distribution and sales framework for HUMIRA (AbbVie is the marketing and manufacturing authorization holder for HUMIRA, while Eisai is responsible for distribution).
In addition, AbbVie and Eisai will continue co-promotion for HUMIRA of indications outside of the gastrointestinal disease field (treatment of rheumatoid arthritis [including prevention of structural joint damage] and the following diseases that do not sufficiently respond to existing treatments: psoriasis vulgaris, arthropathic psoriasis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis).
AbbVie, Eisai and EA Pharma will continue to promote and provide information on the proper use of HUMIRA while making further contributions to improve the quality of life of patients.
1. About HUMIRA
HUMIRA is a fully human anti-TNF-alpha monoclonal antibody which is approved for the following indications in Japan: "treatment of rheumatoid arthritis (including prevention of structural joint damage) and the following diseases that do not sufficiently respond to existing treatments: psoriasis vulgaris; arthropathic psoriasis; ankylosing spondylitis; polyarticular juvenile idiopathic arthritis; intestinal Behcet's disease; moderate to severe active Crohn's disease as remission induction and maintenance therapy; and moderate to severe ulcerative colitis."
2. About AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases.
Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
AbbVie GK was established in Japan in 2013. The company employs 900 people, dedicated to developing and delivering treatments in our therapeutic areas focused on immunology, neonatology, liver disease and neuroscience, where we believe we can make a remarkable impact on the lives of patients. For further information, please visit www.abbvie.co.jp.
3. About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan.
We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our "human health care (hhc)" philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Oncology and Neurology.
For more information about Eisai Co., Ltd., please visit http://www.eisai.com.
4. About EA Pharma
Established in April 2016 through the integration of Eisai's gastrointestinal disease business and AJINOMOTO PHARMACEUTICALS Co., Ltd., EA Pharma is a gastrointestinal specialty pharma with a full value chain including research and development, production and logistics, sales and marketing.
For further information on EA Pharma Co., Ltd., please visit www.eapharma.co.jp.
Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Eisai |
| Nov 20, 2024 10:51 HKT/SGT |
|
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan |
| Nov 20, 2024 09:24 HKT/SGT |
|
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements |
| Nov 15, 2024 16:33 HKT/SGT |
|
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment) |
| Nov 15, 2024 13:31 HKT/SGT |
|
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease |
| Nov 5, 2024 10:35 HKT/SGT |
|
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem" |
| Nov 1, 2024 12:56 HKT/SGT |
|
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| Oct 31, 2024 12:56 HKT/SGT |
|
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference |
| Oct 31, 2024 10:33 HKT/SGT |
|
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) |
| Oct 17, 2024 19:01 HKT/SGT |
|
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association |
| Oct 17, 2024 14:59 HKT/SGT |
|
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia |
| More news >> |
 |
|
|
|
